See more : Regional Health Properties, Inc. (RHE-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Cryoport, Inc. (CYRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryoport, Inc., a leading company in the Integrated Freight & Logistics industry within the Industrials sector.
You may be interested
- Solowin Holdings Ordinary Share (SWIN) Income Statement Analysis – Financial Results
- CDL Investments New Zealand Limited (CDI.NZ) Income Statement Analysis – Financial Results
- Kalyani Commercials Limited (KALYANI.NS) Income Statement Analysis – Financial Results
- Israel Discount Bank Limited (DSCT.TA) Income Statement Analysis – Financial Results
- Shantou Dongfeng Printing Co., Ltd. (601515.SS) Income Statement Analysis – Financial Results
Cryoport, Inc. (CYRX)
About Cryoport, Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.26M | 237.28M | 222.61M | 78.70M | 33.94M | 19.63M | 11.95M | 7.68M | 5.88M | 3.94M | 2.66M | 1.10M | 555.64K | 475.50K | 117.96K | 35.12K | 83.56K | 67.10K | 152.30K | 271.43K |
| Cost of Revenue | 133.92M | 133.40M | 126.03M | 42.36M | 16.59M | 9.39M | 5.99M | 4.58M | 3.99M | 2.77M | 2.22M | 1.59M | 1.39M | 1.30M | 717.71K | 546.15K | 386.37K | 176.94K | 315.65K | 499.65K |
| Gross Profit | 99.33M | 103.87M | 96.58M | 36.33M | 17.35M | 10.24M | 5.97M | 3.10M | 1.89M | 1.17M | 436.96K | -487.28K | -836.82K | -827.48K | -599.75K | -511.03K | -302.81K | -109.84K | -163.35K | -228.22K |
| Gross Profit Ratio | 42.59% | 43.78% | 43.38% | 46.17% | 51.12% | 52.18% | 49.91% | 40.39% | 32.14% | 29.70% | 16.43% | -44.28% | -150.61% | -174.02% | -508.46% | -1,454.93% | -362.37% | -163.68% | -107.26% | -84.08% |
| Research & Development | 18.04M | 15.72M | 16.84M | 9.48M | 3.74M | 1.84M | 1.21M | 598.11K | 550.26K | 352.58K | 409.11K | 425.45K | 491.85K | 449.13K | 284.85K | 297.38K | 166.23K | 87.86K | 254.49K | 98.70K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 17.47M | 9.80M | 7.42M | 6.45M | 5.93M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 13.82M | 7.25M | 5.23M | 4.82M | 4.16M | 2.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.88M | 120.06M | 97.56M | 56.86M | 31.29M | 17.04M | 12.65M | 11.27M | 10.08M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Other Expenses | 49.57M | -5.52M | -2.82M | -929.00K | 772.07K | 77.63K | 14.34K | -6.77K | -9.90K | -4.27K | -13.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -630.00 | -3.00 | 0.00 |
| Operating Expenses | 214.49M | 135.78M | 114.41M | 66.34M | 35.03M | 18.88M | 13.86M | 11.87M | 10.63M | 6.76M | 5.52M | 5.84M | 6.60M | 4.77M | 3.60M | 2.68M | 2.72M | 1.99M | 1.28M | 721.50K |
| Cost & Expenses | 348.41M | 269.18M | 240.44M | 108.71M | 51.62M | 28.27M | 19.85M | 16.44M | 14.62M | 9.53M | 7.74M | 7.42M | 7.99M | 6.07M | 4.32M | 3.23M | 3.10M | 2.16M | 1.59M | 1.22M |
| Interest Income | 0.00 | 8.47M | 3.25M | 761.00K | 784.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.94K | 15.57K | 8.16K | 32.10K | 50.08K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.50M | 6.14M | 4.69M | 2.56M | 1.37M | 69.25K | 15.69K | 139.42K | 1.07M | 1.43M | 784.45K | 72.86K | 527.75K | 618.77K | 7.03M | 2.69M | 1.59M | 228.37K | 80.38K | 85.77K |
| Depreciation & Amortization | 27.49M | 22.77M | 20.25M | 9.87M | 2.42M | 857.94K | 664.83K | 374.20K | 239.23K | 197.94K | 311.59K | 393.96K | 343.03K | 245.48K | 150.09K | 81.98K | 1.34M | 111.22K | 88.75K | 92.60K |
| EBITDA | -66.36M | -6.19M | -248.91M | -20.31M | -14.49M | -8.61M | -7.21M | -13.38M | -8.51M | -5.40M | -18.47M | -5.91M | -6.96M | -5.29M | 1.53M | -13.93M | -2.93M | -1.99M | -1.35M | -857.12K |
| EBITDA Ratio | -28.45% | -15.77% | -9.28% | -39.31% | -49.80% | -43.65% | -65.90% | -109.37% | -148.77% | -142.23% | -706.79% | -538.87% | -1,274.16% | -1,122.18% | -3,424.14% | -8,773.52% | -2,005.44% | -2,958.25% | -887.85% | -315.11% |
| Operating Income | -115.16M | -31.90M | -17.83M | -30.01M | -17.68M | -8.64M | -7.89M | -8.77M | -8.74M | -5.59M | -5.08M | -6.32M | -7.43M | -5.60M | -4.20M | -3.20M | -3.02M | -2.10M | -1.44M | -949.72K |
| Operating Income Ratio | -49.37% | -13.45% | -8.01% | -38.13% | -52.07% | -44.05% | -66.02% | -114.16% | -148.60% | -142.12% | -190.92% | -574.67% | -1,338.05% | -1,177.08% | -3,558.31% | -9,098.32% | -3,613.77% | -3,123.99% | -946.12% | -349.89% |
| Total Other Income/Expenses | 15.81M | -3.19M | -256.01M | -2.73M | -594.90K | -891.03K | -1.36K | -4.34M | -1.08M | -1.43M | -14.49M | -56.38K | -396.65K | -553.60K | -1.45M | -13.51M | -1.54M | -228.37K | -80.38K | -87.59K |
| Income Before Tax | -99.35M | -35.09M | -273.84M | -32.74M | -18.27M | -9.54M | -7.89M | -13.11M | -9.82M | -7.03M | -19.56M | -6.38M | -7.83M | -6.15M | -5.65M | -16.70M | -4.56M | -2.32M | -1.52M | -1.04M |
| Income Before Tax Ratio | -42.59% | -14.79% | -123.02% | -41.60% | -53.83% | -48.59% | -66.03% | -170.70% | -166.89% | -178.52% | -735.50% | -579.79% | -1,409.43% | -1,293.51% | -4,789.89% | -47,555.95% | -5,459.83% | -3,464.31% | -998.90% | -382.17% |
| Income Tax Expense | 239.00K | 2.24M | 1.69M | -45.00K | 61.58K | 19.95K | 5.14K | 5.67K | 3.63K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 800.00 | 800.00 |
| Net Income | -99.59M | -37.33M | -275.53M | -32.69M | -18.33M | -9.56M | -7.90M | -13.11M | -9.82M | -7.03M | -19.57M | -6.38M | -7.83M | -6.15M | -5.65M | -16.71M | -4.56M | -2.33M | -1.52M | -1.04M |
| Net Income Ratio | -42.69% | -15.73% | -123.77% | -41.54% | -54.01% | -48.69% | -66.08% | -170.77% | -166.95% | -178.56% | -735.56% | -579.94% | -1,409.72% | -1,293.84% | -4,791.25% | -47,560.50% | -5,461.75% | -3,466.70% | -999.42% | -382.46% |
| EPS | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| EPS Diluted | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| Weighted Avg Shares Out | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.20M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
| Weighted Avg Shares Out (Dil) | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.22M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus
The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn. , Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced...
SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
NASHVILLE, Tenn. and RANCHO CORDOVA, Calif.
The Schall Law Firm Is Inquiring Into Possible Securities Fraud By Cryoport Inc And Shareholders Are Encouraged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Is Looking Into Cryoport Inc For Possible Securities Law Violations And Encourages Shareholders To Help
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Is Inquiring Into Potential Securities Law Violations By Cryoport Inc And Asks Investors To Help
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Begins Investigation Into Cryoport Inc And Asks Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Opens Investigation Into Cryoport Inc And Encourages Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Initiates Probe Into Allegations Against Cryoport Inc And Motivates Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Reach Out
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the...
Source: https://incomestatements.info
Category: Stock Reports